Table 3 Fukuoka consensus guidelines, 2012 (intraductal papillary mucinous neoplasm—IPMN—and mucinous cystic neoplasm—MCN) and 2017 (intraductal papillary mucinous neoplasm—IPMN)
From: Cystic pancreatic lesions: MR imaging findings and management
2012 Fukuoka consensus | 2017 Revised Fukuoka consensus | ||
|---|---|---|---|
Worrisome features | High-risk stigmata | Worrisome features | High-risk stigmata |
Cyst size > 3 cm | Obstructive jaundice | Cyst size > 3 cm | Obstructive jaundice |
Thickened/enhancing cyst walls | Enhancing mural nodules | Thickened/enhancing cyst walls | Enhancing mural nodules ≥ 5 mm |
MPD dilatation of 5–9 mm | MPD diameter > 10 mm | MPD dilatation of 5–9 mm | MPD diameter > 10 mm |
Non-enhancing mural nodules |  | Enhancing mural nodules < 5 mm |  |
Abrupt changes in the MPD caliber with distal pancreatic atrophy | Â | Abrupt changes in the MPD caliber with Distal pancreatic atrophy | Â |
Lymphadenopathy | Â | Lymphadenopathy | Â |
History of pancreatitis |  | Rapid rate of cyst growth > 5 mm/2 years |  |
| Â | Â | Elevated serum level of CA 19.9 | Â |